Calmark brings investment in production line forward

The Board of Directors of Calmark Sweden AB has today resolved to bring the final step of the automation of the production line for the single-use item forward, to build the last two steps in parallel. The Company has concluded an agreement with SEB, Skandinaviska Enskilda Banken AB (publ), relating to leasing of the production equipment.

The planned extension of the production capacity for the single-use tests was projected to be implemented in a step-by-step manner, with the final step, a fully automated production line, estimated to be achieved in 2021-2022. Following the decision made today this investment will be brought forward so that Calmark can scale up the production volume faster but also achieve significantly reduced manufacturing costs for the single-use tests more quickly.

"I am delighted that SEB gives us this opportunity to bring the final step of the automation forward. Achieving lower manufacturing costs sooner will enable volume sales in the countries where we can do the greatest good," says Anna Söderlund, CEO. "We are looking forward to being able to meet a great demand for our products."

This information is information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 16:50 CET on 16 April 2020.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

 

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 213 25 35
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analyzis method with easier and faster sampling of medical conditions in newborns. The unique test platform, which consists of a reader and single-use products, is expected to be ready for launch in 2020 when three important POC tests are introduced. The WHO estimates that 1.5 billion children will be born worldwide by 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter healthcare chains. In less developed healthcare systems, the product helps save lives. Calmark aims to become the global leader and ultimately to offer all relevant POC tests for the first period of life, regardless of where in the world a baby is born. Read more about Calmark www.calmark.se/eng/home.